Literature DB >> 8568266

Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway.

H Tanaka1, Y Makino, T Miura, F Hirano, K Okamoto, K Komura, Y Sato, I Makino.   

Abstract

The therapeutic effectiveness of ursodeoxycholic acid (UDCA) for various autoimmune liver diseases strongly indicates that UDCA possesses immunomodulatory activities. Experimental evidence also supports this notion, since, for example, UDCA has been shown to suppress secretion of IL-2, IL-4, and IFN-gamma from activated T lymphocytes, and Ig production from B lymphocytes. To investigate the mechanical background of UDCA-mediated immunomodulation, we asked whether UDCA interacts with the intracellular signal transduction pathway, especially whether it is involved in immunosuppressive glucocorticoid hormone action. For this purpose, we used a cloned Chinese hamster ovary cell line, CHOpMTGR, in which glucocorticoid receptor cDNA was stably integrated. In immunocytochemical analysis, we found that treatment with UDCA promoted the nuclear translocation of the glucocorticoid receptor in a ligand-independent fashion, which was further confirmed by immunoprecipitation assays. Moreover, the translocated glucocorticoid receptor demonstrated sequence-specific DNA binding activity. Transient transfection experiments revealed that treatment of the cells with UDCA marginally enhanced glucocorticoid-responsive gene expression. We also showed that UDCA suppressed IFN-gamma-mediated induction of MHC class II gene expression via the glucocorticoid receptor-mediated pathway. Together, UDCA-dependent promotion of translocation of the glucocorticoid receptor may be associated with, at least in part, its immunomodulatory action through glucocorticoid receptor-mediated gene regulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568266

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Authors:  Y Bar-Dayan; M E Gershwin; Y Levi; H Amital; Y Shoenfeld
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

2.  Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.

Authors:  Katsuya Ikuta; Yoshihiro Torimoto; Junko Jimbo; Junki Inamura; Motohiro Shindo; Kazuya Sato; Yoshihiko Tokusashi; Naoyuki Miyokawa; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

Review 3.  Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.

Authors:  Amitkumar Patel; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2016-10-21

4.  Suppression of the HPA axis during extrahepatic biliary obstruction induces cholangiocyte proliferation in the rat.

Authors:  Matthew Quinn; Yoshiyuki Ueno; Hae Yong Pae; Li Huang; Gabriel Frampton; Cheryl Galindo; Heather Francis; Darijana Horvat; Matthew McMillin; Sharon Demorrow
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-06       Impact factor: 4.052

5.  Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes.

Authors:  J D Fontes; S Kanazawa; D Jean; B M Peterlin
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

6.  Genomic and nongenomic cross talk between the gonadotropin-releasing hormone receptor and glucocorticoid receptor signaling pathways.

Authors:  Andrea Kotitschke; Hanél Sadie-Van Gijsen; Chanel Avenant; Sandra Fernandes; Janet P Hapgood
Journal:  Mol Endocrinol       Date:  2009-10-07

Review 7.  5β-Reduced steroids and human Δ(4)-3-ketosteroid 5β-reductase (AKR1D1).

Authors:  Mo Chen; Trevor M Penning
Journal:  Steroids       Date:  2014-02-08       Impact factor: 2.668

Review 8.  Bile-acid-induced cell injury and protection.

Authors:  Maria-J Perez; Oscar Briz
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

Review 9.  Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Authors:  Amardeep Khanna; David E Jones
Journal:  Therap Adv Gastroenterol       Date:  2017-09-07       Impact factor: 4.409

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.